Not independent
Tenure on this board
6.2 yrs
Meeting calendar
IBO · Annual meeting · Wednesday, November 5, 2025
Impact Biomedical Inc
8 nominees · 3 ballot items.
Election of eight directors, ratification of the independent auditor Grassi & Co., and an advisory vote on executive compensation are the matters to be voted on at the meeting.
Market cap
$604M
1Y TSR
+164.8%
Board grade
D
Record date
Sep 8, 2025
Filing
DEF 14A
Meeting concluded · Nov 5, 2025
Follow how the vote landed and what changed on Impact Biomedical Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FOREight directors are to be elected to serve until the next annual meeting.
- 2
Ratification of the Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Grassi & Co. Certified Public Accountants, P.C. as the Company's independent registered public accounting firm for fiscal year 2025.
- 3
Advisory Vote on Executive Compensation
ManagementBoard: FORNon-binding advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in this Proxy Statement.
Director elections
Nominees on the ballot8
Not independent
Tenure on this board
2.0 yrs
Independent
Tenure on this board
5.8 yrs
Independent
Tenure on this board
2.0 yrs
Independent
Tenure on this board
2.0 yrs
Independent
Tenure on this board
2.0 yrs
Independent
Tenure on this board
2.0 yrs
Not independent
Tenure on this board
3.0 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 0.9% | 952,204 | $438K |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 0.8% | 808,689 | $372K |
| 3 | STATE STREET CORP | 0.6% | 607,897 | $280K |
| 4 | VANGUARD FIDUCIARY TRUST CO | 0.5% | 589,428 | $271K |
| 5 | BlackRock, Inc. | 0.2% | 259,940 | $120K |
| 6 | NORTHERN TRUST CORP | 0.2% | 235,475 | $108K |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.2% | 232,959 | $107K |
| 8 | CITADEL ADVISORS LLC | 0.0% | 49,567 | $23K |
| 9 | Vanguard Global Advisers, LLC | 0.0% | 32,201 | $15K |
| 10 | JANE STREET GROUP, LLC | 0.0% | 24,527 | $11K |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Impact Biomedical Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Weave Communications IncWEAV
Special meeting·Oct 22, 2026·$589M
Tilray Brands IncTLRY
Annual meeting·Nov 18, 2026·$538M
Varex Imaging CorpVREX
Special meeting·Oct 28, 2026·$778M
Sanara Medtech IncSMTI
Special meeting·Sep 30, 2026·$322M
Phibro Animal Health CorpPAHC
Annual meeting·Nov 3, 2026·$1.4B
Biolife Solutions IncBLFS
Special meeting·Oct 5, 2026·$1.9B
Reference
Frequently asked questions
- When is the Impact Biomedical Inc 2025 annual meeting?
- Impact Biomedical Inc (IBO) holds its 2025 annual shareholder meeting on Wednesday, November 5, 2025.
- What is the record date for the Impact Biomedical Inc 2025 meeting?
- The record date for the Impact Biomedical Inc 2025 meeting is Monday, September 8, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Impact Biomedical Inc's 2025 meeting?
- The board is presenting 8 director nominees at the Impact Biomedical Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Impact Biomedical Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Impact Biomedical Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.